Is the watch and wait approach adequate after comprehensive surgical staging in invasive Stage I epithelial ovarian cancer? The Norwegian Radium Hospital Experience

Objectives: The aim of this Study on stage I epithelial ovarian cancer (EOC) wits to see if our different treatment policies after 1995. when lymph node staging and paclitaxel were introduced, have affected the survival, try to define risk groups for relapse and who should get adjuvant chemotherapy (AC). Methods: A retrospective study based on record information from all patients with invasive EOC stage I operated at the Norwegian Radium Hospital (NRH) 1984-2001, in total 252 patients. Results: Total 5-year survival was 83 and 82%. respectively. in both time periods. We found age and histology to be significant prognostic factors for overall Survival (OS) (p < 0.01), From 1995 survival was significantly better for those who had been properly staged than for the others (p = 0.02), with a 5-year survival rate of 87 vs 64%. Those who did not get chemotherapy but were staged, had a significantly better overall survival than those who were not (p = 0.02), with a 5-year survival of 93 vs 77%. In the period 1995-2001 the patients who received no adjuvant treatment lived longer than those who underwent chemotherapy and/or radiotherapy (p = 0.03). In the first period 17% had no adjuvant treatment vs 58% in the last. Patients in a high-risk group getting AC had a tendency toward better-survival than those who did not (p = 0.09). Conclusions: Patients with Stage I low and medium risk EOC do not need AC if properly staged. For the high-risk group the optimal AC has not yet been established.

Early stage ovarian cancer

[1] Norway Institute of Population-Based Cancer Research: Cancer in Norway 2005. Cancer Registry of Norway Institute of Population-Based Cancer Research, 2006

[2] Ozols R.F., Rubin S.C., Thomas G.M., Robboy S.J.: “Epithelial ovarian cancer”. In: Hoskins W.J., Perez C.A., Young R.C. (eds.) Principles and Practice of Gynaecologic Oncology, 3rd edition. Philadelphia, Lippincott, Williams & Wilkins, 2000, 981.

[3] Vergote I., De Brabanter J., Fyles A., Bertelsen K., Einhorn N., Sevelda P. et al.: “Prognostic importance of degree of differentiation and cyst rupture in Stage I invasive epithelial ovarian carcinoma”. Lancet, 2001, 357, 176.

[4] Kristensen G.B., Kildal W., Abeler V.M., Kaern J., Vergote I., Tropé C.G. et al: “Large-scale genomic instability predicts longterm outcome for women with invasive Stage I ovarian cancer”. Ann. Oncol., 2003, 14, 1494.

[5] Trope C., Kaern J., Høgberg T., Abeler V., Hagen B., Kristensen G. et al.: “Randomized study on chemotherapy in Stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument”. Ann. Oncol., 2000, 11, 281.

[6] Obermair A., Fuller A., Lopez-Varela E., van Gorp T., Vergote I., Eaton L. et al.: “A new prognostic model for FIGO Stage I epithelial ovarian cancer”. Gynecol. Oncol., 2007, 104, 607.

[7] Anttila M.A., Ji H., Juhola M.T., Saarikoski S.V., Syrjänen K.J.: “The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer”. Int. J. Gynecol. Pathol., 1999, 18, 42.

[8] Skirnisdottir I., Seidal T., Gerdin E., Sorbe B.: “The prognostic importance of p53, bcl-2, and bax in early Stage epithelial ovarian carcinoma treated with adjuvant chemotherapy”. Int. J. Gynacol. Cancer, 2002, 12, 265.

[9] Oksefjell H., Sandstad B., Tropé C.: “Ovarian cancer Stage IIIC. Consequences of treatment level on overall and progression-free survival”. Eur. J. Gynaecol. Oncol., 2006, 27, 209.

[10] Trimbos J.B., Vergote I., Bolis G., Vermorken J.B., Mangioni C., Madronal C. et al.: “Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial”. J. Natl. Cancer Inst., 2003, 95, 113.

[11] Young R.C., Decker D.G., Wharton J.T. et al.: “Staging laparotomy in early ovarian cancer”. JAMA, 1983, 250, 3072.

[12] Zanetta G., Rota S., Chiari S., Bonazzi C., Bratina G., Torri V. et al.: “The accuracy of staging: An important prognostic determinator in Stage I ovarian carcinoma: A multivariate analysis”. Ann. Oncol., 1998, 9, 1097.

[13] Trope C., Kaern J.: “Adjuvant chemotherapy for early-stage ovarian cancer: Review of the literature”. J. Clin. Oncol., 2007, 25, 2909.

[14] International Collaborative Ovarian Neoplasm Trial 1: “A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer”. J. Nat. Cancer Inst., 2003, 95, 125.

[15] International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant Chemotherapy in Ovarian Neoplasm Trial: “Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma”. J. Natl. Cancer Inst., 2003, 95, 105.

[16] Swart A.C. on behalf of ICON collaborators: “Long-term followup of women in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON 1)”. ASCO 2007; abstract nr 5509 (oral presentation).

[17] McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Patridge E.E, Look K.Y. et al.: “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and IV ovarian cancer”. N. Engl. J. Med., 1996, 334, 1.

[18] du Bois A., Luck H.J., Meier W., Adams H.P., Mo´´bus V., Costa S. et al.: “A randomized clinical trial of cisplatin/paclitaxel as firstline treatment of ovarian cancer”. J. Natl. Cancer Inst., 2003, 95, 1320.

[19] Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A. et al.: “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2003, 21, 3194.

[20] Bell J., Brady M.F., Young R.C., Lage J., Walker J.L., Look K.Y. et al.: “Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynaecologic Oncology Group study”. Gynecol. Oncol., 2006, 102, 432.

[21] Vergote I.B., Vergote-De Vos L.N., Abeler V.M., Aas M., Lindegaard M.W., Kjørstad K.E. et al.: “Randomized trial comparing cisplatin with radioactive phosphorus or whole abdominal irradiation as adjuvant treatment of ovarian cancer”. Cancer, 1992, 69, 741.

[22] Onda T.,Yoshikawa H.,Yokota H.,Yasugi T., Taketani Y.: “Assessment of metastasis to aortic and pelvic lymph nodes in epithelial ovarian carcinoma”. Cancer, 1996, 78, 803.

[23] Baiocci G., Raspagliesi F., Grosso G., di Re F., Fontanelli R.: “Early ovarian cancer: Is there a role of systematic pelvic and paraaortic lymphadenectomy?”. Int. J. Gynecol. Cancer, 1998, 8, 103.

[24] Trimbos J.B., Schueler J.A., van der Burg M., Hermans J., van Lent M., Heintz A.P.M. et al.: “Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer”. Cancer, 1991, 67, 597.

[25] Monga M., Carmichael J.A., Shelley W.E., Kirk M.E., Krepart G.V., Jeffrey J.F. et al.: “Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging”. Gynecol. Oncol., 1991, 43, 195.

[26] Vergote I., Trimbos B.J.: “Treatment of patients with early epithelial ovarian cancer”. Curr. Opin. Oncol., 2003, 15, 452.

[27] Colombo N., Pecorelli S.: “What have we learned from ICON1 and ACTION?”. Int. J. Gynecol. Cancer, 2003, 13 (suppl. 2), 140.

[28] Bolis G., Colombo N., Pecorelli S., Torri V., Marsoni S., Bonazzi C. et al.: “Adjuvant treatment for early epithelial ovarian cancer: Results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P)-GICOG: Gruppo Interregionale Collaborativo in Ginecologia Oncologica”. Ann. Oncol., 1995, 6, 887.

[29] Liavaag A.H., Dorum A., Fossa S.D., Tropé C., Dahl A.A.: “A controlled study of fatigue, quality of life, somatic and mental morbidity in epithelial ovarian cancer survivors: How lucky are the lucky ones?”. J. Clin. Oncol., 2007, 25, 2049.

[30] Travis L.B., Holowaty E.J., Bergfeldt K., Lynch C.F., Kohler B.A., Wiklund T. et al.: “Risk of leukemia after platinum-based chemotherapy for ovarian cancer”. N. Engl. J. Med., 1999, 340, 351.